Zimmer Biomet Holdings, Inc., commonly referred to as Zimmer Biomet, is a leading global medical device company headquartered in the United States. Founded in 1927, the company has established a strong presence in the orthopaedics and musculoskeletal sectors, focusing on innovative solutions for joint reconstruction, trauma, spine, and dental applications. With major operational regions across North America, Europe, and Asia-Pacific, Zimmer Biomet is renowned for its advanced products, including joint replacement implants and surgical instruments. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted partner in the healthcare industry. Notably, Zimmer Biomet's unique offerings, such as personalised surgical solutions and cutting-edge robotic technologies, enhance patient outcomes and streamline surgical procedures, solidifying its market leadership.
How does Zimmer Biomet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zimmer Biomet's score of 50 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Zimmer Biomet reported total greenhouse gas (GHG) emissions of approximately 10,191,000 kg CO2e for Scope 1 and about 67,195,000 kg CO2e for Scope 2, resulting in a combined total of approximately 77,386,000 kg CO2e (market-based). This marks a significant reduction from previous years, where the total market-based emissions for 2023 were about 83,219,000 kg CO2e and for 2022 were approximately 89,801,000 kg CO2e. Zimmer Biomet has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 55% by 2030, using 2017 as the baseline year. Additionally, the company has committed to reducing its Scope 3 emissions from purchased goods and services by 15% by 2030, with a 2019 baseline. In September 2023, Zimmer Biomet formalised its commitment to achieve net-zero GHG emissions by 2050, in alignment with the Science Based Targets initiative (SBTi). The company's emissions data is sourced directly from Zimmer Biomet Holdings, Inc., with no cascaded data from parent organisations. These commitments reflect Zimmer Biomet's proactive approach to addressing climate change within the healthcare equipment and supplies sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zimmer Biomet has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Zimmer Biomet's sustainability data and climate commitments